
NYSE:ARDT
This summary was created by AI, based on 3 opinions in the last 12 months.
Ardent Healthcare Partners Inc. (ARDT) has seen mixed sentiments from analysts. Initially labeled as a Top Pick, the stock triggered a stop-loss recommendation at $10.50 due to a significant price drop of 18.3%. Despite this setback, experts reiterate the company's potential, citing plans to expand with 18 additional urgent care clinics set for 2025 and a successful recent earnings report showing a 38% increase. Trading at 7x earnings and exhibiting a 25% return on equity, the company appears to be on a growth trajectory, leveraging AI and virtual nursing to enhance productivity while managing its debt responsibly. Analysts project a price target between $19.08 and $19.27, suggesting a notable upside potential of approximately 28%.
Ardent Healthcare Partners Inc. is a American stock, trading under the symbol ARDT (previously ARDT-N on Stockchase) on the New York Stock Exchange (ARDT). It is usually referred to as NYSE:ARDT or ARDT
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on ARDT (previously ARDT-N on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Ardent Healthcare Partners Inc..
Ardent Healthcare Partners Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-13. Read the latest stock experts ratings for Ardent Healthcare Partners Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Ardent Healthcare Partners Inc..
Ardent Healthcare Partners Inc. is followed by 12 investors on Stockchase and is a trending stock that is worth watching.
On 2026-08-14, Ardent Healthcare Partners Inc. (ARDT) stock closed at a price of $10.91.
Our PAST TOP PICK with ARDT has triggered its stop at $10.50. To remain disciplined, we recommend covering the position at this time. When combined with previous guidance, this will result in a net investment loss of 18%.